230 related articles for article (PubMed ID: 35177078)
1. Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy.
Wang M; Hu Q; Huang J; Zhao X; Shao S; Zhang F; Yao Z; Ping Y; Liang T
J Nanobiotechnology; 2022 Feb; 20(1):85. PubMed ID: 35177078
[TBL] [Abstract][Full Text] [Related]
2. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
3. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53
Qiu J; Feng M; Yang G; Cao Z; Liu Y; You L; Zhang T
Cancer Lett; 2023 Feb; 554():216020. PubMed ID: 36442772
[TBL] [Abstract][Full Text] [Related]
5. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer.
Tong QS; Miao WM; Huang H; Luo JQ; Liu R; Huang YC; Zhao DK; Shen S; Du JZ; Wang J
Small; 2021 Jul; 17(29):e2101208. PubMed ID: 34145747
[TBL] [Abstract][Full Text] [Related]
6. Macrophage-derived biomimetic nanoparticles enhanced SDT combined with immunotherapy inhibited tumor growth and metastasis.
Chen S; Ma T; Wang J; Liang S; Liao H; Tan W; Chen M; Zhou X; Xu Y; Wang L; Niu C
Biomaterials; 2024 Mar; 305():122456. PubMed ID: 38184961
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Knockdown of Immune Suppressive Markers by Tumor Microenvironment-Responsive Multifaceted Prodrug Nanomedicine.
Zhang L; Wang J; Cui H; Zheng H; Yin X; Lin J; Wang Y; Zhao Y; Li H; Chen Q
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12864-12881. PubMed ID: 36856003
[TBL] [Abstract][Full Text] [Related]
8. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
10. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
11. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.
Zhao P; Xu Y; Ji W; Zhou S; Li L; Qiu L; Qian Z; Wang X; Zhang H
J Nanobiotechnology; 2021 Jun; 19(1):181. PubMed ID: 34120612
[TBL] [Abstract][Full Text] [Related]
12. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
14. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
[TBL] [Abstract][Full Text] [Related]
15. Spatially targeting and regulating tumor-associated macrophages using a raspberry-like micellar system sensitizes pancreatic cancer chemoimmunotherapy.
Li T; Chen D; Liu H; Tao Y; He X; Zang S; Li J; Zhang L; Li M; Liu J; He Q
Nanoscale; 2022 Sep; 14(36):13098-13112. PubMed ID: 35972382
[TBL] [Abstract][Full Text] [Related]
16. Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy.
Feng X; Chen Z; Liu Z; Fu X; Song H; Zhang Q
Int J Pharm; 2023 May; 639():122970. PubMed ID: 37084832
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
18. Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer.
Chen Q; Zhang L; Li L; Tan M; Liu W; Liu S; Xie Z; Zhang W; Wang Z; Cao Y; Shang T; Ran H
J Nanobiotechnology; 2021 Dec; 19(1):449. PubMed ID: 34952587
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1.
Wang H; Tang Y; Fang Y; Zhang M; Wang H; He Z; Wang B; Xu Q; Huang Y
Nano Lett; 2019 May; 19(5):2935-2944. PubMed ID: 30950276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
